The vascular and cardioprotective effects of liriodenine in ischemia-reperfusion injury via NO-dependent pathway
Journal
Nitric Oxide - Biology and Chemistry
Journal Volume
11
Journal Issue
4
Pages
307-315
Date Issued
2004
Author(s)
Abstract
Liriodenine is an aporphine derivative isolated from the plant Fissistigma glaucescens. Electrophysiological action, particularly the blockage of Na + and K + channels, contributes to the drug's well-known anti-arrhythmic action. However, liriodenine's cardioprotective efficacy and the relation of the channel blockages to the efficacy are poorly known, as is the drug's effect on coronary flow and endothelial function. The present study evaluated the protection conveyed by liriodenine to myocardium and coronary endothelial cells under conditions of ischemia-reperfusion and to assess the involvement of a nitric oxide (NO)-dependent mechanism. In the Langendorff model utilizing Sprague-Dawley rat hearts, the left main coronary artery was occluded for 30 min and reperfusion for 120 min. Liriodenine (1 μM) significantly promoted the recovery of coronary flow and decreased myocardial infarction compared with vehicle-treated hearts. The drug attenuated the reduction of endothelial reactivity and NO release. To simulate the condition that occurs in the ischemic stage, human umbilical vein endothelial cells (HUVEC) were cultured in serum free conditions. Liriodenine showed concentration-dependent effects on cell viability associated with anti-apoptosis under serum-deprivation. Liriodenine prevented eNOS reduction in serum-deprived HUVEC and ischemia-reperfusion hearts. The vascular and cardioprotective effects were reversed by N G-nitro-l-arginine methyl ester. Another Na + and K + channel blocker with similar activities as liriodenine (quinidine) failed to protect endothelial cells and myocytes. These results demonstrate that liriodenine reduces the extent of cardiovascular injuries under ischemia-reperfusion conditions mainly by preserving the eNOS and the NO production. ? 2004 Elsevier Inc. All rights reserved.
Subjects
eNOS; HUVEC; Ischemia-reperfusion heart; Liriodenine; Nitric oxide; Quinidine
SDGs
Other Subjects
liriodenine; n(g) nitroarginine methyl ester; nitric oxide; nitric oxide synthase; potassium channel blocking agent; quinidine; sodium channel blocking agent; animal model; apoptosis; artery occlusion; article; cardiovascular disease; cell culture; cell line; cell viability; concentration response; controlled study; coronary artery blood flow; endothelium cell; heart infarction; heart muscle; heart muscle cell; heart protection; human; human cell; ischemia; isolated heart; left coronary artery; male; nonhuman; priority journal; rat; reperfusion injury; Animals; Aporphines; Cardiotonic Agents; Coronary Circulation; Endothelial Cells; Endothelium, Vascular; Humans; Male; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Quinidine; Rats; Rats, Sprague-Dawley; Time Factors; Fissistigma
Type
journal article